NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered Tesamorelin from Nexaph? Mail in a sample (US only) and let us test it.

Test my supply
+8 more ↓
37%
Finnrick rating
#107 of 114 Tesamorelin vendors
10 of 30 classifiable tests passed
natural 33% · customers 4.5★ (24)
methodology · Purity focus
Finnrick analysis · Tesamorelin

Nexaph tesamorelin shows a high-concern, volatile purity record with severe misses at 63.84%, 88.39%, and 93.1% plus one identity failure. Recent tests mixed after an April rebound; fills reached +27%.

methodology →
vendor intelligence report
Vendor Intelligence Report: Nexaph

Nexaph's public pages point to Shanghai Nexa Pharma Co, Nevis terms, and an Indiana operating footprint without resolving the legal counterparty. The report maps shared COA infrastructure, sister-brand trails, crypto rails, and a documented batch-sterility thread.

39 pages9 risk factors assessed12 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.25
89%
12
2
Tirzepatide
$1.13
77%
65
3
KLOW
$5.72
77%
3
4
Retatrutide
$2.46
76%
108
5
PT-141
-
72%
3
6
BPC-157
$1.51
64%
21
7
Ipamorelin
$1.30
60%
10
8
Cagrilintide
$3.50
51%
13
9
CJC-IPA
$3.96
45%
1
10
Tesamorelinselected
$2.88
37%
30
11
TB-500
$1.61
37%
7
12
Sermorelin
-
36%
3
13
CJC-1295
$3.40
35%
9
14
Semaglutide
$1.90
35%
15
15
MOTS-c
$1.88
29%
6
16
NAD+
$0.04
28%
3
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%29 Jun 2025: 0%16 Jul 2025: 4%16 Jul 2025: 9%24 Jul 2025: 19%24 Jul 2025: 18%4 Aug 2025: 17%4 Aug 2025: 16%6 Aug 2025: 20%31 Aug 2025: 27%9 Sep 2025: 25%9 Oct 2025: 32%23 Oct 2025: 31%4 Nov 2025: 29%17 Nov 2025: 32%17 Nov 2025: 31%25 Nov 2025: 29%17 Dec 2025: 28%9 Jan 2026: 28%19 Jan 2026: 27%18 Feb 2026: 31%2 Mar 2026: 31%18 Mar 2026: 31%25 Mar 2026: 30%28 Apr 2026: 33%28 Apr 2026: 35%20 May 2026: 38%16 Jun 2026: 37%1 Jul 2026: 35%10 Sep 2026: 34%16 Sep 2026: 37%15 Nov 2026: current 37%0%28%37%Jun 25Nov 26
Showing Tesamorelin tests only
Peptide testing

Ordered Tesamorelin from Nexaph? Mail in a sample (US only) and let us test it.

Test my supply
Nexaph Tesamorelin test history
COA-backed lab tests
1-10 of 30

About Nexaph test results from Finnrick

Nexaph is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 16 peptides and 309 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Nexaph peptides in this dataset are BPC-157 (21 tests) and Semaglutide (15 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 200 recent tests.

Corrections
No corrections.
Peptide testing

Ordered Tesamorelin from Nexaph? Mail in a sample (US only) and let us test it.

Test my supply